SYMPOSIA

Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org
Poster Presentations
[PP-121] Ref. No: 280
Abuse of tianeptine: A case report
Hüsameddin Özer, Atilla Erol
Sakarya Teaching and Research Hospital, Psychiatry Clinic, Sakarya, Turkey
E-mail: husamozer@mynet.com
Tianeptine is an atypical antidepressant, which modestly enhances the mezolimbic release of dopamine. Tianeptine is an antidepressant
that is accepted as not being abused by patients. However, there have been some case reports regarding abuse and/or addiction to it.
The abuse of tianeptine is rare and so far has only been reported in patients with pre-existing multi substance abuse disorders. A total of
141 cases of abuse were reported between 1989 and 2004. The patients usually sought and experienced a psychostimulant effect. The
stimulant effect of tianeptine has been specifically emphasized in some case reports of tianeptine abuse in the literature.
In this poster, a twenty year-old female patient, who received tianeptine treatment for depression and developed tianeptine dependence
is presented. In our case, the patient was taking sixty pills daily. Although she took sixty pills, her biological tolerance was excellent and
hepatic and hematological parameters were not affected, similar to the findings of other reports in the literature.
This case emphasizes that while prescribing tianeptine treatment clinicians should be careful using it in patients with substance abuse
problems, as reported by other case reports in the literature.
Key words: Tianeptine abuse, tianeptine dependence
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S197
[PP-122] Ref. No: 282
GWAS with AHP based SNP prioritization approach to identify SNP biomarkers
for Alzheimer’s disease
Onat Kadıoğlu 1 , Gürkan Üstünkar 2 , Yeşim Aydın Son 3
1 Middle East Technical University, Bioinformatics Graduate Program Ankara, Turkey
2 Middle East Technical University, Informatics Institute Department of Information Science, Ankara, Turkey
3 Middle East Technical University, Informatics Institute Department of Health Informatics, Ankara, Turkey
E-mail: onat.kadd@gmail.com
Genome wide association studies (GWAS) is defined as search for biological variance associated with certain phenotypes and diseases
among individuals in a population depending on statistical analysis. Combined p-value approach has been introduced recently and
is defined as the second-wave GWAS. It helps mapping of significant SNPs to genes and pathways to evaluate SNP-gene-disease
associations. Identification of enriched genes and pathways significantly associated with diseases can be performed via this approach.
The major bottleneck of current standard GWAS approaches is the prioritization of statistically significant results. Our group has recently
developed a novel Analytical Hierarchical Process (AHP) based on a structured SNP prioritization algorithm. SNPs are scored according
to their biological relevance in terms of their genomic location and functional consequence, evolutionary conservation, and genedisease
association. The recently developed METU-SNP application integrates GWAS, combined p-value while utilizing AHP based SNP
prioritization algorithms. Combined p-value and AHP prioritization approach for GWAS of Alzheimer’s Disease (AD) has been utilized for
the SNP-disease association of AD for the first the time in this study with METU-SNP software.
The results from the analysis of two different sets of AD genotyping data with the newly proposed AHP based prioritization yield promising
results for both datasets. For the ADNI data, all the top 100 SNPs according to AHP scoring map to OMIM associated genes and 18 of
them map to AD linked genes. For the GenADA data, all the top 100 SNPs according to AHP scoring map to OMIM associated genes and
37 of them map to AD linked genes. Glycolysis and gluconeogenesis, leukocyte migration, axon guidance, actin filament polymerization,
cell adhesion, DNA fragmentation during apoptosis, fatty acid metabolism, and negative regulation of cell proliferation are common
pathways residing at top 100 pathways according to combined p-value for pathways that are observed in GWAS results of both data sets.
GWAS of both data with METU-SNP confirms the literature for AD associated genes; A2M, ABCA1, ACE, APOA1, APP, CHRNA7, IL1A,
LDLR, LPL, MPO, PTGS2, SORL1. rs3781835 at SORL1, rs4343, and rs4351 at ACE1 are SNPs with high AHP scores are also listed to be AD
associated at PharmGKB database. Moreover, CT and TT genotype of rs6313 at HTR2A gene indicates resistance to the treatment with
antipsychotic drugs for AD patients presenting delusional symptoms. As presented here METU-SNP is a powerful tool with a novel AHP
based prioritization algorithm implemented, which can lead to discovery of new associations at SNP, gene, and pathway level. In near
S197